Merus expects the FDA to make a decision on the application in February after reviewing additional manufacturing information it submitted.

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

The funding will allow CUH to buy new equipment for administering treatments such as CAR T-cell therapies, reducing patients' need to travel long distances.

In JAMA Neurology, the group challenged the "movement" to define Alzheimer's disease as a "purely biological entity based on biomarker findings." ...

After years of persistence, genetic counselors at UT Southwestern got BCBS of Texas to fix a system error that was leading to payment denials for services.

National Cancer Center Japan has partnered with Precision Medicine Asia and Paradigm Health to develop a streamlined system to facilitate trials.

NEW YORK – Beam Therapeutics on Tuesday disclosed initial clinical data, including one patient death, in a Phase I/II trial of its investigational sickle cell disease (SCD) gene-editing therapy ...

NEW YORK – Inify Laboratories on Tuesday said it has partnered with researchers at Karolinska Institutet to improve prostate cancer diagnosis through artificial intelligence-driven image analysis.

The government payor said it will separately pay for specialized diagnostic radiopharmaceuticals without transitional pass-through payment status.

The FDA has cleared an investigational new drug application enabling the company to begin a Phase I trial of HG202 in patients with the eye disorder.

The company will use the funds to enroll a registrational trial for its investigational gene therapy NGN-401 for Rett Syndrome.

In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.